Thanks work, Jody. Good by thank begin for during at Thanks would thanking PDL their adaptiveness. to perseverance and you pandemic. afternoon and for my engagement colleagues everyone at and teams us. joining the and the and COVID-XX their hard like Noden dedication to LENSAR I
to safe good corporate our working pandemic. to of managed our are from to report have progress while most the to continue we that today home make have the priorities during pleased continued ensuring I advance We to offices. entire working their am whom conditions team,
monetization X, fully the Slide our to of Turning the executing engaged stockholders. our we in for company assets the of to unlock are value full
As attractive on confident they companies. and/or you remain of high We with in believe may monetize or form our stockholders. proceeds individually maximizing plan cash of the to assets. sell or operating to approach as or or buyers net in whole a We are public standalone assets quality as to disciplined with the our assets a company know, our the focus is financial strategic
vote. entitled Meetings Moving week. earlier related that statement may on of of Slide SEC record XX, May our be the close this filed preliminary you to to will to by proxy the X, business the XXXX read Stockholders with have now at we Annual XXXX
Time. We annual XX:XX will in meeting stockholders of at be our Pacific XXXX format a virtual on XX, beginning holding July a.m.
the voting of to at We meeting. the of results end expect announce the
available timing, to dissolution. viability PDL accounting and legal – board a dissolution interest determined strategy there the risks, sale is company and plan of financial consulting advisors to the is our consummated, the to the the statement whole with all and carefully add Board on As the our impact is and preliminary stockholders. not alternatives the previously potential best management our proxy of respect stockholders, within stated, in considering the with event After dissolution outlining
allow down of Dissolution factors shareholders discussion from by the the stock. the after its is during is of considered this preliminary the operations shares liquidation an or due of common after will A process maturity wind the company’s the holders proxy liability of to of plan and key subject outstanding for the the to period. of protect our included dissolution both statement. during company Approval assets efficient of many approval in dissolution the claims
of In shareholders. dissolution goal will overhead expenses a our distributions total ultimately with reduce to allow addition, the increasing to company
and I’d any review operated. is plan several period in of certificate of Inc and Delaware the dissolution. company for at filing will key potential required the Delaware The State disputes exist assets. of like to proposed allows managing still remaining time and the PDL where with It of claims for solidly resolving least distribution and three any of monetization litigation, points years the wind-down the dissolution laws after This is facilitating purposes. for
It dissolution of also The strategic State of the do with not running when the stockholders is These approve period begins the remaining of of Delaware. first filed provides certificate the and for issues distribution. for dissolution. shareholders club and a dissolution plan handling the any on final
our explore stockholders. returning We continue to will the alternatives will capital corporate continue board to and for existence
process. last legal all a by stated our and how management On and with rights, monetization and Noden, goals stockholders the key LENSAR, advisors deliver analyzing sale the financial board or to company have Our four the assets, Evofem namely best completing ambitious been of XXXX. maximize outside of call, from holding of we our our value royalty our together whole we end our monetization to
be it potential While assets not buyers assets probable that of disposition other timing the delayed progress or some makes business of on may recognized could date, possible of of process impact we are beyond if and COVID-XX to of the pandemic by that XXXX. sales our cause our certain other encouraged the we delays, which of monetization our the these
stockholders. our dissolution delay our the In interest of the that affect view to PDL capture best both value to due of dissolution shareholders’ will The believe of this dissolution not for of dissolution, filing permits plan changes the of if the certificate for circumstances in regarding implementation in monetization our the we abandon decision that approval dissolution can the of the and process. and and we through asset of timeline flexibility the board or getting plan or
leading us in the have to our of advise announced X, investment banks on this as call, Now Slide engaged on we process. execution last monetization conference an
the million Let of dividend of me PDL May our been XX.X Evofem on in Evofem the of average that We announced special totality stockholders. ownership Evofem to board Biosciences. investment. draw progress our review distribution the date our has common us our of approved of with stock on Torreya shares advising Xth to starting directors one-time of sale interest a
aggressively mentioned explored the the all sale press this our our beginning the financial careful decision release, of year, made advising we we a Leerink management monetization private and and and a Tuesday’s in after letter and of via matters. pursue advisors: with Evofem SVB board Since As of consideration Torreya alternatives the shares number consultation with sales.
in in the stock they number we best is of the came PDL current through of COVID-XX, this shareholders regarding that impact the their For conclusion environment, receive the shares distribution a make distribution. This distribution including shareholders. interest to the own investment will reasons, of decisions enable to all Evofem
XXXX this of Subject process May distribution. May XX, XXXX. the the XX, review close be record business me of will the Let of certain to PDL as Evofem of to stockholders shares distributed on on conditions,
shares rata Evofem PDL a common May the stockholders stock to form record XX. So of place distribution of will dividend take of in on of pro each
May As of PDL of XXXX, shares common million approximately XXX.X has outstanding. X, stock
estimate ratio based we PDL of PDL X.XXX distribution of number, final be that for the will determined PDL they common this on outstanding stock approximately number Evofem on hold. shares on shares stockholders The the date. share record common receive will each stock common of Based
shares to be of lieu registered period freely Instead, any PDL and will be state, local federal, not that fractional that in distributed. would consult otherwise stockholders shares they received. tax will Please of receive stockholders We'll of to Evofem have be Evofem non-U.S. respect tradable. share a Distributed PDL recommend of stock U.S. fraction no with and Evofem of the will lock-up and note common cash that subject their any consequences fully will tax advisors distribution.
XX. May get Evofem, FDA about yesterday. of case now in not their did to for chance product a you date earnings currently PDUFA share pregnancy the under prevention call first a review to with is a candidate, by Phexxi quarter Evofem’s listen brief of lead me U.S. the Let update
This Evofem of label their they the guarantee Phexxi. progress with that Evofem nonetheless, announced plans the also FDA FDA, regarding on is by April this XX, in approved is not listen at to discussions are yesterday you Phexxi recording launch for Phexxi, encouraging. that but proposed webcast but a may the its evofem.com. reported will be for
potential path Finally, our monetize of Evofem continue to to up purchase to stock. X.X shares we to pursue common Evofem warrants million
price strike of warrants Evofem Our $X.XX. at
monetization turn our processes X. me to other on now Let Slide
sale our its royalty sale previously has the As of Both and work in royalty the is robust. or portfolio announced, company financial whole Securities portfolio. whole as advisers the company on acting BofA with been of connection the streams
process competitive are sale the royalty of we on of a the and with We track have execution. its assets
This have are to COVID-XX of have been subsidiary received. noticeably Noden to Pharma track. sell we on and been of will the the affected encouraged remain has Torreya and leading of by so process maximizing leads the our number pandemic we quality process by
committed maximize we the to pursue while and appropriate of development the technology path for value its fully are to We success stockholders. next-generation its PDL LENSAR
opportunities between ultimately cash to value of engaged to LENSAR, our distributed sale options that monetization liabilities non-cash million. our and SVB and $XXX be proxy, Leerink present, the LENSAR stockholders evaluate public lead we estimate million that In settling our the of have be and assets after PDL at spin-off. to available process may to other our this $XXX the two We or
$X per to of based XX, between stockholders a non-cash of our share the shares approximately $X on of dissolution. and This PDL cannot amount in connection outstanding as with cash broad available certainty, is This because the April cash in form the XXXX. a to current distribute we assets and range predict distribution implies of the of number
predict say our calculating we assumptions if to with and range of and We liabilities. I distributable dispose review in proxy number of preliminary you to to our refer both value, of are of non-cash the statement it’s the value or all substantially we all made any, able assumptions. a of all certainty until estimated these Now the assets liabilities, and can the assets,
considered with beginning XX% X, now Let the prior-year net some to $X and surgeries, We U.S. elective LENSAR, our our key markets, world. elective provide assets. cases Slide heart cataract period. Europe million me the complete and and Korea on are progressively both over of across pandemic the an the almost COVID-XX across declined quarter including key advanced most which China sales updates the for Asian started in and On with surgeries first The South
expect in the reopen to lined part participants, In we second begin the market other cataract that with surgery of the industry later quarter. will progressively
to not fourth First, in up to position the are at In in guidance year. the returning rest third for the ramping levels this hopefully in LENSAR in to revenue world, of considerable in time. and in pre-COVID-XX market, of close provide quarter Asia uncertainty this of in subsequently then we XXXX the a light the before quarter the
company COVID-XX’s said, In technology. That LENSAR. view its market, cataract the is what timeline makes extend expect impact we monetization for of LENSAR a the attractive surgery particularly of on to customization. positioned rebound a treatment well for downturn, and effectively, is procedure as an accuracy building its upon cataracts the LENSAR greater that to from innovator but of position COVID-XX the require
technology with management visually XX% remains the surgery, this treatment laser, the tissue-specific to uncorrected and patients enables treatable astigmatism post-surgery. astigmatism cataracts which best-in-class IV significant astigmatism. of the of surgeon XX% and Streamline features cataract largely but prior Between have LENSAR optimized of
ability which system, a in compact combine seamlessly we we to its laser GENX we the a switch to will substantially as providing system believe GENX; competitive and phacoemulsification position. Importantly, between the state-of-the-art referred two next-generation LENSAR’s the that enhance surgeons technologies. femtosecond workstation, single
pursue to in the is well of LENSAR Further, and opportunities. development GENX end capitalized of LENSAR the ensure of commercialization. position commercial with the XXXX. GENX intellectual technology GENX and with debt by conduct development progressing the secures application of any financing. a and well. GENX be a LENSAR’s would premier without operates expected spinners, for is submission public that XXX(k) other LENSAR we business, case XXXX The launch third-party targeting property of to its USFDA would In growth
Slide received to of impact of cash in $XX.X priorities believe In rights $XX.X assets that our ethical in mainly million of quarter. the are royalty related quarter X. treatment our X on portfolio assets up be to our from from of the net diabetes. royalty year-ago to some Turning XXXX, much on assessing in million We all essential the pandemic impacted of likely less products words the our are these to in We Type by the portfolio COVID-XX. are first
Pharma on Noden to Switching XX. Slide
quarter profitability generated Tekturna off. mitigate operating of and income in XXXX. generic the the of million impact Our U.S. of Noden of paying strategy to the competition increase in $X.X first the is
by approximate an products control their unique used pleased XX% of are target who our U.S. need Tekturna to and are Noden and life hypertension. Pharma share the maintaining generic are advancing We Tekturna patients, threatening these Rasilez drugs market. authorized that
any We dependent values. haven’t from income seen impact significant
So, in PDL’s In connection opportunity losses XXXX opportunity with a carryback paid recognize years. they certain Cares loss process, carrybacks. to Act carry significant income monetization XXXX years. XXXX and the years to cash provides taxes back easy and made eligible PDL, in tax certain taxable the incurred five
program of Turning at convertible stocks XX.X of million common share our aggregate the on per shares million $XXX.X average XX. XXXX, our million share. to cost notes of and $XXX.X stock. we X.X repurchase issuance an $XXX first million repurchased of shares million we the for March of principal purchased in $X.XX Through XX, amounts XXXX, our an million $XX.X of quarter In of common for Slide
million As had $XX.X we of program. March repurchase our XX, remaining under
financial discuss With to our to that, the turn Ed? I’d over like Ed call results. to
